secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001664710-25-000062
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros doses first patient in Phase 3 RENEW trial of elritercept; $10M milestone from Takeda
--------------------------------------------------------------------------------

- First patient dosed in Phase 3 RENEW trial of elritercept for adults with transfusion-dependent anemia with very low, low, or intermediate risk MDS.
- Milestone payment of $10 million triggered from Takeda under global license agreement.
- Keros received $200M upfront in Feb 2025; eligible for milestones exceeding $1.1B and tiered royalties.
- RENEW is global, randomized, double-blind, placebo-controlled; primary endpoint is reduction in red blood cell transfusions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/0001664710-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/kros-20250717.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer